Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.49 |
| ▸ | NOS1 | P29475 | 10/20 | 0.49 |
| ▸ | NOS3 | P29474 | 7/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PDE8A | O60658 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097246 | 0.78 | NOS2 (0.49) | NOS2NOS1NOS3DYRK1ACCR1 | |
| SCHEMBL4011600 | 0.77 | DYRK1A (0.43) | NOS2NOS1NOS3DYRK1AALDH1A1 | |
| SCHEMBL4382615 | 0.74 | NOS1 (0.59) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL3307860 | 0.73 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL4011598 | 0.72 | TACR1 (0.41) | NOS1DYRK1AALDH1A1MAPTKDM4E | |
| SCHEMBL3307858 | 0.71 | NOS2 (0.59) | NOS2NOS1NOS3CCR1CCR5 | |
| SCHEMBL1061501 | 0.70 | NOS2 (0.62) | NOS2NOS1NOS3CCR1CCR5 | |
| Hydrochloric Acid SCHEMBL219320 | 0.69 | — | — | |
| SCHEMBL3020319 | 0.69 | — | — | |
| SCHEMBL6068566 | 0.69 | NOS1 (0.47) | NOS2NOS1NOS3CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | NOS2 998/4885NOS1 1302/4885NOS3 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.